NCT04398524 | Cancer Search

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.

phase

Phase 2

status

Recruiting

enrollment

score

start date

2021-07-01

last updated

2022-01-03

biomarkers

CDKN2A Overexpression

HPV Positive

conditions

drugs

cemiplimab

ISA101b

source

Houston, Texas

The University of Texas M. D. Anderson Cancer Center

Boston, Massachusetts

Beth Israel Deaconess Medical Center

Portland, Oregon

Providence Portland Medical Center

Tampa, Florida

H. Lee Moffitt Cancer Center & Research Institute

St. Louis, Missouri

Washington University

Buffalo, New York

Roswell Park Cancer Institute

Duarte, California

City of Hope National Medical Center

7 sites
Page 1 of 1